NCT07073690View on ClinicalTrials.gov

Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

Active, not recruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

November 26, 2025

Study Completion Date

November 26, 2025

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Luspatercept

According to the product label

Trial Locations (1)

Unknown

Zhijian Xiao, Tianjin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT07073690 - Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China | Biotech Hunter | Biotech Hunter